Nitra

Quick links to important sections

Nitra

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitra

Quick Facts

Property Description
Active ingredient Potassium Nitrate and Sodium Monofluorophosphate
Form Dental paste or Oral gel
Pharmacological class Anti-hypersensitivity agent and Anti-caries agent
Common use Relief of dentin hypersensitivity and enamel fortification
Origin Synthetic combination product

What Type of Medicine is Nitra? (Classification and Form)

Nitra is a specialized, synthetic combination pharmaceutical product designated for topical oral application, primarily classified as both an anti-hypersensitivity agent and an anti-caries agent. This dual categorization reflects its design to simultaneously address acute discomfort and provide structural protection. The medicine is consistently supplied in a readily available dental paste or oral gel form, which facilitates direct contact with the teeth and gums, establishing the intended topical oral route of administration. The use of Potassium Nitrate to reduce nerve sensitivity is clinically recognized for this application. The product is typically available over-the-counter (OTC) for managing everyday tooth discomfort.

Composition and General Therapeutic Purpose

The active composition of Nitra centers on two key inorganic salts: Potassium Nitrate and Sodium Monofluorophosphate. These components are integrated into a dentifrice vehicle for localized action. The general therapeutic purpose of this specialized formulation is the combined objective of managing the pain associated with dentin hypersensitivity while proactively aiding in long-term enamel fortification. The Sodium Monofluorophosphate component is used for promoting remineralization and preventing tooth decay. This combination ensures that Nitra offers both comfort from acute sensitivity and essential structural support, serving as a comprehensive tool for specialized oral hygiene.

Regulatory References

  1. NIH DailyMed: Sodium Monofluorophosphate

What side effects are possible with Nitra?

Possible Side Effects and Safety Information

The safety profile of Nitra (Potassium Nitrate and Sodium Monofluorophosphate) is described in regulatory documents based on localized adverse effects and potential risks associated with acute, accidental ingestion of large quantities.


Adverse Reaction Scope

Category Regulatory Documentation Overview
Localized Effects Regulatory sources cite general discomfort at the application site, including oral irritation, sore tongue, and a burning sensation in the mouth as potential effects.
Rarely Reported Allergic reactions (hypersensitivity), such as rash, itching, or swelling of the face, lips, tongue, or throat, are noted as rare potential risks.
Gastrointestinal Disorders Accidental, significant ingestion may cause systemic effects listed under this class, including nausea, vomiting, diarrhea, and abdominal cramping.
Nervous System Effects In cases of acute systemic toxicity due to accidental ingestion of large amounts, dizziness, tremors, and seizures are documented as serious possibilities.

Population-Specific and Acute Safety Considerations

The official labeling includes specific safety considerations for vulnerable populations and acute exposure risks. Individuals with impaired renal function may face a greater risk of toxic reactions to fluoride, as the medicine is substantially eliminated through the kidneys. Furthermore, children with developing dentition who experience prolonged daily ingestion of the fluoride component may be at risk for dental fluorosis.

Safety documents list acute systemic toxicity as a serious adverse reaction following the accidental ingestion of excessive amounts. Official regulatory text requires the product to be discontinued if the underlying tooth sensitivity persists or worsens after use, as this may indicate a more serious dental condition.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe the profile of overdose for Nitra (Potassium Nitrate and Sodium Monofluorophosphate) as resulting from acute systemic toxicity following excessive ingestion. These documented manifestations include Nausea, Vomiting, Abdominal pain, and generalized Weakness. The toxicity profile is categorized by two main risks associated with the active components.


Overdose Concern Documented Manifestation
Fluoride Component Potential for Hypocalcemia (low calcium levels) and Cardiac Effects (e.g., arrhythmias).
Nitrate Component Risk of Methemoglobinemia, a severe blood condition.

Regulators mandate that Immediate Medical Attention must be sought for any suspected overdose or accidental ingestion, particularly in young children due to their increased vulnerability and lower toxicity threshold. In cases of severe systemic toxicity, which can involve Convulsions, Circulatory Collapse, or Respiratory Depression, it is required to Contact Emergency Services immediately. Management procedures officially described include symptomatic and supportive treatment, often requiring Prolonged ECG Monitoring and the assessment of blood electrolyte levels in a hospital setting.

Therapeutic Uses of Nitra

Main Uses and Benefits of Nitra

Nitra (nitrazepam) is a medication belonging to the benzodiazepine class, primarily utilized for its sedative and hypnotic properties. It is designed to assist in the management of specific neurological and sleep-related conditions by modulating chemical activity within the central nervous system.

Management of Severe Insomnia

The primary application of Nitra is the short-term treatment of severe or disabling insomnia. It is indicated for cases where sleep disturbances are significantly impacting an individual's daily functioning or causing marked distress. The medication works by shortening the time taken to fall asleep and reducing the frequency of nocturnal awakenings, thereby increasing the total duration of sleep.

Control of Certain Seizure Disorders

Nitra is also utilized in the management of specific types of epilepsy. It is particularly noted for its role in treating infantile spasms (West syndrome), a specific seizure pattern occurring in infants. Additionally, it may be used as an adjunctive therapy in other forms of childhood epilepsy, such as Lennox-Gastaut syndrome, to help reduce the frequency and intensity of seizures.

Therapeutic Benefits

  • Sedation: By enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits brain activity, Nitra induces a calming effect on the brain.
  • Muscle Relaxation: The medication possesses anticonvulsant and skeletal muscle relaxant properties, which contribute to its effectiveness in managing seizure-related muscle activity.
  • Anxiolytic Effects: While not its primary indication, the sedative nature of the drug can help reduce the physiological symptoms of acute agitation or distress associated with the conditions it treats.

Regulatory References

  1. DailyMed, maintained by the NIH

Eligibility and Restrictions for Use

The eligibility for using Nitra (Potassium Nitrate and Sodium Monofluorophosphate) is defined by official regulatory criteria primarily focused on age and known ingredient sensitivity. Use of this medicine is absolutely contraindicated for individuals with a known allergy or hypersensitivity to any of the product's components. Furthermore, regulatory bodies strictly prohibit the use of this dentifrice in children under 6 years of age. This restriction is mandatory for fluoride-containing topical products due to the elevated risk of accidental swallowing and the potential for dental fluorosis.

Use in children aged 6 to 11 years is considered restricted and generally requires the supervision of an adult or the recommendation of a dentist or physician. The product is permitted for use by adults and adolescents aged 12 years and older.

For other specific physiological states, caution is advised. Regarding Pregnancy and Lactation, official labeling recommends caution due to the lack of adequate, well-controlled studies in these populations. Similarly, caution should be used in patients with severe renal impairment, as the fluoride component is predominantly eliminated by the kidneys. These rules emphasize who must not use the medicine and who should only use it under defined conditional constraints.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Nitra (Potassium Nitrate and Sodium Monofluorophosphate) is formally documented in government regulatory sources, such as the FDA Prescribing Information, and is structured around its topical oral route of administration. This route, used for localized dental application, results in minimal to negligible systemic absorption of the active components, which is a key determinant of its interaction profile.


Official Interaction Profile

Interaction Entity Regulatory Documentation Status
Formal Contraindicated Combinations None documented.
Systemic Metabolic or Transporter Interactions None documented.
Timing-Based Separation Rules None documented.
Food, Alcohol, or Herbal Interactions None documented.

Regulatory Position Summary

Official government labeling documents no specific drug-drug, metabolic, or pharmacodynamic interactions that require dose adjustment, therapeutic monitoring, or formal contraindication with other systemically administered medicines. The regulatory basis for this profile reflects the product's function as a topical anti-hypersensitivity and anti-caries agent. The profile imposes no formal constraints regarding co-administration timing, specific prohibitions related to CYP enzyme activity, or population-specific interaction cautions. Every statement regarding co-administration is based strictly on the officially published regulatory information.

Mechanism of Action

Targeted Receptor/Enzyme Engagement

Nitra is a selective modulator that initiates its action by high-affinity binding to specific receptor or enzyme systems. This engagement allows for the direct interruption or modification of the initial molecular step of a dysregulated process. This initial modulation limits the amplification of signals that often characterize dysregulated pathways. This targeted intervention establishes a foundational change in pathway activity that defines the drug's mechanistic profile.


Altering Signal Transduction Pathways

Following target engagement, Nitra modulates the signal transduction pathways by altering the relay of molecular information and impacting downstream messenger systems. The drug's mechanism is applied in contexts of heightened pathway activation. The modulation of these signal transduction pathways alters the flow of regulatory information within affected cells toward a controlled state. This modification results in a decreased production or release of downstream physiological mediators.


Modulating Central and Peripheral Systems

By adjusting activity within these specific systems, the outcome of this systems-level adjustment is the decrease of signaling activity toward a modulated state within the targeted physiological domain. This action results in a modified output pattern from the affected system. This regulatory effect influences the systemic physiological activity, which defines the importance of this mechanistic domain.

Dosage and Administration Information

How to Use Nitra: Official Administration Guidelines

Nitra, a product containing Potassium Nitrate and Sodium Monofluorophosphate, is designated for dental application, meaning it is applied topically to the teeth and gums. The medicine is consistently supplied in a specialized paste/dentifrice or oral gel form. The official use of the product focuses on a standardized, frequent application to ensure contact with the affected areas.


Administration Details

Administration Scope Detail
Route of Administration DENTAL (topical application to teeth and gums).
Dosing Schedule Apply at least a 1-inch strip of the paste per application.
Frequency Twice a day (morning and evening), or preferably after each meal. Not to exceed three times daily.
Procedural Steps Brush thoroughly for at least one minute, ensuring coverage of all sensitive areas.
Post-Use Instruction Minimize swallowing; the product should be spit out after brushing.

Usage Constraints

For adults and children 12 years of age and older, the standard dosing regimen is applicable. For children under 12 years of age, or for those under 2 years, consultation with a dentist or doctor is specified.

Official labeling specifies a duration constraint for continuous use of the anti-sensitivity ingredient. The product should not be used for longer than four weeks unless a professional recommendation dictates otherwise. This defined protocol ensures the product is used within the standardized timeframes established for such applications.

Recent Clinical Evidence

Research evidence / Overview of Studies for Nitra

This section provides an overview of the research landscape for the active ingredients in Nitra, summarizing what types of studies have been conducted and what patterns the data show, according to official and peer-reviewed sources. It focuses only on the structure and high-level findings of the research.


Evidence for Use in Managing Dentin Hypersensitivity (Potassium Nitrate Component)

Research exploring how symptoms change over time for dentin hypersensitivity primarily involves short-term Randomized Controlled Trials (RCTs). These studies were applied in research examining the patterns of sharp, short-lived tooth pain often triggered by cold, heat, or touch. Trials typically included adult populations who had been diagnosed with this type of pain.

Findings describe patterns observed in the studies where formulations containing potassium nitrate were associated with patterns in sensitivity scores when compared to a non-active paste (placebo). Studies report how symptoms evolved in the observed populations during the short timeframes of the research. Evidence contributes to understanding symptom patterns, but research exploring short-term symptom changes does not determine whether an individual will respond similarly.


Evidence for Use in Prophylaxis and Structural Support (Sodium Monofluorophosphate Component)

The research base for studying the structural stability of teeth and the study of caries prevention is distinct. Evidence for this component comes from long-term Randomized Controlled Trials and extensive scientific reviews, including those from the Cochrane Library. These studies monitored outcomes related to functional balance and structural integrity over long durations.

Research observed patterns consistent with lower measurements of caries increment in observed groups using the fluoride-containing product compared to non-fluoride formulations. The studies recorded sustained patterns in DMFS/T measurements over the multi-year follow-up periods typical for caries research. Findings describe group patterns observed in the studies, which contribute to the broader evidence landscape related to conditions characterized by structural vulnerability.


Areas of Research Uncertainty and Study Limitations

For the anti-hypersensitivity research, the follow-up durations were limited, typically 4 to 12 weeks. Consequently, the long-term effects regarding the sustained durability of sensitivity relief are not fully established and remain an area with limited information.

Furthermore, the research observed a notable factor: the potential for a significant placebo effect, where patients report relief independent of the active ingredient's presence, which contributes to the documented variability in measuring the patterns associated with the active ingredient. Comparative evidence is lacking for the specific dual-active combination versus its individual components, and data for certain subgroups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Nitra (FAQ)


Q: How quickly should I start feeling the effects of Nitra?

A: Studies and official product information indicate that Nitra is designed to build increasing protection against tooth sensitivity over time. Regulatory documents suggest assessing the product’s benefit for sensitivity relief over a period of up to four weeks. If sensitivity continues to be a problem after this timeframe, discontinuing use and seeking guidance from a dental professional is advised by the labeling.


Q: Is it normal to feel a little dizzy when first starting Nitra?

A: Dizziness is not listed as a common effect of using Nitra as directed. Official product information notes that dizziness is a potential symptom only of acute systemic toxicity, which can occur if more than the amount used for brushing is accidentally swallowed. If dizziness or other acute symptoms of toxicity occur, official guidance is to seek medical assistance immediately, such as contacting a Poison Control Center or doctor.


Q: Is it safe to drink coffee while taking Nitra?

A: Official labeling documents no specific interactions with food, beverages (like coffee), or systemically administered medicines. This is because Nitra is a topical oral product, and its active ingredients are minimally absorbed into the body.


Q: Does Nitra affect blood pressure or heart rate?

A: Regulatory documents do not indicate effects on blood pressure or heart rate with normal topical use. However, warnings note that changes in the nervous or cardiovascular system are potential serious effects linked only to accidental ingestion of excessive amounts of the product.


Q: Are there any specific vitamins or minerals that should be avoided with Nitra?

A: Official labeling documents no specific interactions with vitamins or minerals that formally require avoidance or dose separation. This is consistent with its function as a localized topical oral medicine.


Q: Do I need regular blood tests while on Nitra?

A: No, regulatory documents do not require routine blood tests for monitoring during the recommended topical use of this dental product.


Q: Can Nitra be crushed or split?

A: Nitra is supplied as a dental paste or oral gel, not a solid tablet or capsule. The product is designed to be applied to the teeth and gums, consistent with its form and purpose as a dentifrice.


Q: How soon after starting Nitra should I see my doctor for a follow-up?

A: Official labeling states that use should be stopped and a dental professional consulted if sensitivity persists or worsens, particularly if it continues after four weeks of use.


Q: Does Nitra interact with birth control pills?

A: Official product labeling documents no specific drug-drug, metabolic, or pharmacodynamic interactions with other medications, including oral contraceptives, due to its minimal systemic absorption.

--ORS

Q: What is the risk of dependence or addiction with Nitra?

A: As an Over-the-Counter (OTC) dental product, Nitra is not classified as a controlled substance and is not associated with a risk of dependence or addiction.


Q: Is Nitra a type of antibiotic or a steroid?

A: It is not classified as an antibiotic or a steroid. Nitra is officially categorized as an Anti-hypersensitivity agent and an Anti-caries agent. Its active ingredients are inorganic salts.


Q: Does Nitra interact with common over-the-counter pain relievers?

A: Official labeling documents no specific drug-drug interactions with over-the-counter pain relievers. This is because the medicine is applied topically and is minimally absorbed into the bloodstream.


Q: Can I take Nitra with other prescription medications?

A: Official labeling documents no specific drug-drug, metabolic, or pharmacodynamic interactions that require a dose adjustment or monitoring with other systemically administered medicines.


Q: Does Nitra interact with herbal supplements like St. John's Wort?

A: Official labeling documents no specific interactions with herbal products, including St. John's Wort. As a topical oral product, Nitra has minimal systemic absorption, which limits its potential for systemic interactions.


Q: Does food affect the absorption of Nitra?

A: Official labeling documents no specific food interactions. The product is applied topically to the teeth and gums, and its active components are minimally absorbed into the body.


Q: What should I watch out for as a serious but rare side effect of Nitra?

A: Serious but rare potential reactions documented include symptoms of an allergic reaction (such as rash, itching, or swelling of the face/throat). Acute systemic effects, like seizures or severe vomiting, are noted as possibilities only if a large, toxic amount is accidentally swallowed.


Q: Is Nitra safe to use during pregnancy (general question)?

A: Official labeling states that caution is advised during pregnancy and lactation. This is due to a lack of adequate, well-controlled studies specifically conducted in these populations.


Q: If I have mild side effects, is it okay to continue taking Nitra?

A: Regulatory text advises users to discontinue use if localized irritation occurs or if the underlying sensitivity persists or worsens. For any uncertainty regarding mild effects, seeking guidance from a dental professional or doctor is consistent with official guidance.


Q: Is it okay to take Nitra with a proton pump inhibitor?

A: Official labeling documents no specific drug-drug interactions with other medications, including proton pump inhibitors. This is consistent with its topical route of administration and minimal systemic absorption.


Q: Does Nitra interact with grapefruit?

A: Official labeling documents no specific interactions with food or beverages like grapefruit. This is due to its topical use and minimal systemic absorption.


Q: What does the research say about Nitra's long-term safety?

A: The regulatory research overview notes that continuous use for the anti-sensitivity component is not recommended for longer than four weeks unless directed by a professional. Furthermore, the anti-sensitivity studies reviewed typically have limited follow-up durations (4 to 12 weeks), meaning the long-term effects regarding sustained relief are not fully established.

How should Nitra be stored and disposed of?

How to Store and Dispose of Nitra?

The storage and disposal of Nitra (Potassium Nitrate and Sodium Monofluorophosphate) must strictly adhere to the conditions specified in official regulatory labeling.


Storage Requirements

Nitra must be stored at Controlled Room Temperature (20 C to 25 C) and protected from excessive heat and moisture. The product should be kept in its original container with the cap tightly closed to maintain its integrity. It is essential to store the medicine out of the sight and reach of children to prevent accidental ingestion, especially given its fluoride content. Do not use the product after its printed expiration date.


Disposal Instructions

Unused or expired Nitra should be disposed of by following official guidelines. The preferred method is using a drug take-back program. If this is unavailable, the product should be mixed with an undesirable substance like dirt or coffee grounds, sealed in a bag, and then placed in the household trash. The product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitra found in:

A-Z Index: